Company intelligence / Profile preview

AXOVAN

Allschwil, Basel-Landschaft, Switzerland

Ownership: Private
Development stage: Other

Overview

Axovan was a Swiss biopharmaceutical company focused on the discovery and development of novel small molecule drugs targeting G protein-coupled receptors (GPCRs). The company's lead program was clazosentan (formerly AXV-03), a selective endothelin receptor antagonist designed to prevent cerebral vasospasm following subarachnoid hemorrhage. Founded by a team of former Roche scientists, Axovan leveraged its expertise in GPCR biology to build a pipeline of candidates for cardiovascular and neurological disorders. The company was acquired by Actelion in 2003 to strengthen Actelion's specialty pipeline in the hospital market.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on AXOVAN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AXOVAN.

Explore the full profile